Literature DB >> 8608633

Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope.

N A Staines1, N Harper, F J Ward, V Malmström, R Holmdahl, S Bansal.   

Abstract

The purpose of the study was to map the dominant T cell epitope of the CB11 sequence of CII in RTlu haplotype rats and to determine if, when used as a synthetic peptide, it would induce tolerance to protect against CIA. A dominant epitope corresponding to residues 184-198 included in the sequence of the CB11 fragment of bovine CII was identified in proliferation assay using peptides in an epitope scanning system using synthetic peptides of 15 amino acids, overlapping by 12 amino acids. This epitope is bovine-specific, but cross-reacts with the corresponding rat peptide. Minor epitopes in the bovine CB11 sequence was also autoantigenic. Use of independently synthesized and purified 184-198 peptide confirmed its dominance in the T cell responses of arthritic rats. The peptide itself was not arthritogenic. Cells from lymph nodes draining arthritic feet were particularly responsive to the dominant peptide sequence, and showed evidence of epitope spreading to include reactions to at least four subdominant epitopes. Mucosal tolerance was successfully induced by instilling CII into the nose of rats before induction of CIA: this was found to delay the onset of disease, reduce mean disease severity, shift the anti-CII antibody response to favour antibodies of the IgG1, rather than the IgG2b isiotype, and to reduce T cell reactivity to both CII and to the 184-198 peptide. The dominant 184-198 peptide itself had the same tolerogenic effects when given nasally to rats daily, on the 4 days immediately preceding the induction of CIA. Two forms of CIA with acute and delayed disease onset were each modified by pre-treatment with the peptide. This study demonstrates that mucosal tolerance to CII can be induced by delivering it nasally in a way similar to that achieved previously by oral delivery, and that the use of an immunodominant epitope contained in a synthetic peptide will also suppress the immunologic and arthritic responses to collagen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608633      PMCID: PMC2200363          DOI: 10.1111/j.1365-2249.1996.tb08289.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.

Authors:  B Metzler; D C Wraith
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

Review 2.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

Authors:  G B Fields; R L Noble
Journal:  Int J Pept Protein Res       Date:  1990-03

3.  Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.

Authors:  G Ku; M Kronenberg; D J Peacock; P Tempst; M L Banquerigo; B S Braun; J R Reeve; E Brahn
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

4.  Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats.

Authors:  H S Thompson; N A Staines
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

5.  Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection.

Authors:  E Michaëlsson; M Andersson; A Engström; R Holmdahl
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

6.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

7.  Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity.

Authors:  N Seki; Y Sudo; T Yoshioka; S Sugihara; T Fujitsu; S Sakuma; T Ogawa; T Hamaoka; H Senoh; H Fujiwara
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

8.  Identification and characterization of a tolerogenic T cell determinant within residues 181-209 of chick type II collagen.

Authors:  L K Myers; S W Cooper; K Terato; J M Seyer; J M Stuart; A H Kang
Journal:  Clin Immunol Immunopathol       Date:  1995-04

9.  Tolerogenic activity of polymerized type II collagen in preventing collagen-induced arthritis in rats.

Authors:  H S Thompson; B Henderson; J M Spencer; S M Hobbs; J V Peppard; N A Staines
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

10.  Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis.

Authors:  L K Myers; J M Stuart; J M Seyer; A H Kang
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  32 in total

1.  Antigen presentation of Type II collagen in rats.

Authors:  B Catchpole; N A Staines; A S Hamblin
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

Review 2.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 3.  Inhibition of human T-cell responses by allergen peptides.

Authors:  M Larché
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

4.  Suppression of murine collagen-induced arthritis by nasal administration of collagen.

Authors:  L K Myers; J M Seyer; J M Stuart; A H Kang
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

5.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

Review 6.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

8.  Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Authors:  Inger Gjertsson; Karen L Laurie; James Devitt; Steven J Howe; Adrian J Thrasher; Rikard Holmdahl; Kenth Gustafsson
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

9.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Development and evaluation of transgenic rice seeds accumulating a type II-collagen tolerogenic peptide.

Authors:  Fujio Hashizume; Shingo Hino; Misako Kakehashi; Tetsuya Okajima; Daita Nadano; Naohito Aoki; Tsukasa Matsuda
Journal:  Transgenic Res       Date:  2008-06-18       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.